IGF-1 LR3 vs HGH Fragment 176-191

A detailed comparison to help you understand the differences and choose the right peptide for your research goals.

IGF-1 LR3

IGF-1 LR3 (Long R3 Insulin-like Growth Factor-1) is a modified version of IGF-1 with extended half-life and enhanced potency. The modifications prevent binding to IGF binding proteins, increasing bioavailability.

Full details →

HGH Fragment 176-191

HGH Fragment 176-191 is the fat-reducing portion of the growth hormone molecule. Unlike AOD-9604 (which has an additional tyrosine), this is the exact fragment of HGH responsible for lipolytic effects.

Full details →

Side-by-Side Comparison

AspectIGF-1 LR3HGH Fragment 176-191
MechanismBinds to IGF-1 receptors to promote protein synthesis, muscle growth, and fat metabolism. The LR3 modification (13 amino acid extension and arginine substitution) extends half-life from minutes to 20-30 hours.Mimics the lipolytic region of growth hormone, stimulating fat breakdown and inhibiting lipogenesis without affecting blood sugar or promoting growth. Works independently of GH receptors.
Typical DosageResearch protocols typically use 20-100mcg daily, often divided into multiple injections or administered bilaterally to target muscles.Typical dosing: 250-500mcg daily, often split into 2-3 doses. Usually administered on empty stomach, often with fasted cardio.
AdministrationIntramuscular injection (site-specific growth) or subcutaneous for systemic effects. Often cycled 4-6 weeks on, equal time off.Subcutaneous injection. Best results when used fasted and combined with exercise. Avoid eating for 30 minutes post-injection.
Side EffectsHypoglycemia, joint pain, water retention, potential jaw/hand growth with extended use, and injection site reactions.Generally well-tolerated. May cause injection site irritation, temporary lethargy, or headache. Does not affect blood glucose significantly.
Best For

What They Have in Common

Both IGF-1 LR3 and HGH Fragment 176-191 are commonly used for:

Key Differences

Ready to Learn More?